| Abnormal breath testing in IBS: a meta-analysis ED Shah, RJ Basseri, K Chong, M Pimentel Digestive diseases and sciences 55, 2441-2449, 2010 | 240 | 2010 |
| BF3−H2O Catalyzed Hydroxyalkylation of Aromatics with Aromatic Aldehydes and Dicarboxaldehydes: Efficient Synthesis of Triarylmethanes … GKS Prakash, C Panja, A Shakhmin, E Shah, T Mathew, GA Olah The Journal of Organic Chemistry 74 (22), 8659-8668, 2009 | 132 | 2009 |
| Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis ED Shah, HM Kim, P Schoenfeld The American journal of gastroenterology 113 (3), 329, 2018 | 118 | 2018 |
| Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence? E Shah, A Rezaie, M Riddle, M Pimentel Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of …, 2014 | 118 | 2014 |
| Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis ED Shah, JP Farida, CA Siegel, K Chong, GY Melmed Inflammatory bowel diseases 23 (4), 570-577, 2017 | 98 | 2017 |
| Digestive manifestations in patients hospitalized with coronavirus disease 2019 BJ Elmunzer, RL Spitzer, LD Foster, AA Merchant, EF Howard, VA Patel, ... Clinical Gastroenterology and Hepatology 19 (7), 1355-1365. e4, 2021 | 96 | 2021 |
| Evaluation of harm in the pharmacotherapy of irritable bowel syndrome E Shah, S Kim, K Chong, A Lembo, M Pimentel The American journal of medicine 125 (4), 381-393, 2012 | 91 | 2012 |
| Placebo effect in clinical trial design for irritable bowel syndrome E Shah, M Pimentel Journal of neurogastroenterology and motility 20 (2), 163, 2014 | 50 | 2014 |
| Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome ED Shah, MS Riddle, C Chang, M Pimentel Journal of neurogastroenterology and motility 18 (2), 200, 2012 | 44 | 2012 |
| Systematic review: hepatosplenic T‐cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event … ED Shah, ES Coburn, A Nayyar, KJ Lee, JL Koliani‐Pace, CA Siegel Alimentary pharmacology & therapeutics 51 (5), 527-533, 2020 | 38 | 2020 |
| Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review WD Chey, ED Shah, HL DuPont Therapeutic Advances in Gastroenterology 13, 1756284819897531, 2020 | 38 | 2020 |
| Examining balloon expulsion testing as an office-based, screening test for dyssynergic defecation: a systematic review and meta-analysis ED Shah, JD Farida, S Menees, JR Baker, WD Chey Official journal of the American College of Gastroenterology| ACG 113 (11 …, 2018 | 36 | 2018 |
| The time is now: a guide to sustainable telemedicine during COVID-19 and beyond ED Shah, ST Amann, JJ Karlitz The American journal of gastroenterology, 2020 | 29 | 2020 |
| Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation ED Shah, CV Almario, BMR Spiegel, WD Chey Journal of Neurogastroenterology and Motility 24 (2), 299, 2018 | 28 | 2018 |
| Presentation and characteristics of abdominal pain vary by irritable bowel syndrome subtype: results of a nationwide population-based study ED Shah, CV Almario, BM Spiegel, WD Chey The American journal of gastroenterology 115 (2), 294, 2020 | 27 | 2020 |
| Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis ED Shah, JK Salwen-Deremer, PR Gibson, JG Muir, S Eswaran, ... Clinical Gastroenterology and Hepatology 20 (1), 136-144. e31, 2022 | 23 | 2022 |
| Adverse events appear to unblind clinical trials in irritable bowel syndrome E Shah, K Triantafyllou, AA Hana, M Pimentel Neurogastroenterology & Motility 26 (4), 482-488, 2014 | 23 | 2014 |
| ALIMENTARY TRACT BJ Elmunzer, RL Spitzer, LD Foster, AA Merchant, EF Howard, VA Patel, ... Clinical Gastroenterology and Hepatology 19 (7), 1355-1365, 2021 | 22 | 2021 |
| Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation ED Shah, S Suresh, J Jou, WD Chey, RW Stidham The American journal of gastroenterology 115 (4), 596, 2020 | 20 | 2020 |
| Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome E Shah, M Pimentel Alimentary pharmacology & therapeutics 39 (9), 973-983, 2014 | 20 | 2014 |
Mark PimentelCedars-Sinai Medical Center在 cshs.org 的电子邮件经过验证
